Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Basilar Artery Stenosis Presenting With Acute Onset Vertigo and Unilateral Sensorineural Hearing Loss: A Case Report
Baig, Sarah , Hogan, Douglas, Ghozy, Sherief A., Saha, Ram K. , Ghozy, Sherief

Mayo Clinic

Clinical Neuroimaging | April 8, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1002/neo2.70065 Get It

ABSTRACT Sudden sensorineural hearing loss (SSNHL) is most often idiopathic or related to benign conditions such as Meniere's disease. However, SSNHL caused by vertebrobasilar ischemia is rare and may precede life‐threatening neurological deficits. We present the case of a 67‐year‐old male with hypertension and hyperlipidemia who developed acute vertigo, left‐sided hearing loss, dysarthria, right facial droop, and right‐sided weakness. Initial non‐contrast CT was unremarkable, but computed tomography angiography (CTA) revealed a near‐occlusive thrombus in the mid‐basilar artery. MRI showed an acute infarct in the left cerebellum within the anterior inferior cerebellar artery (AICA) distribution, which supplies the internal auditory artery. Subsequent audiometry confirmed bilateral SSNHL, more severe on the left. The patient was outside the thrombolysis window but underwent cerebral angiography, which confirmed chronic left vertebral occlusion and high‐grade basilar stenosis. He was started on dual antiplatelet therapy and high dose statin therapy and discharged to rehabilitation with residual vertigo and hearing loss. This case emphasizes that SSNHL and vertigo can be early signs of posterior circulation stroke. High‐grade basilar stenosis affecting AICA flow may compromise perfusion to the auditory and vestibular systems. Clinicians should maintain a high index of suspicion for vertebrobasilar ischemia in patients presenting with audiovestibular symptoms, even in the absence of classic stroke findings. Early imaging with MRI and CTA is critical for diagnosis. Recognizing these atypical presentations enables timely management and may reduce long‐term neurologic impairment.
Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children
Marefi, Amaar , Grasso, E , McLendon, Loren , Narula, Sona , Waldman, Amy , Hopkins, Sarah , Banwell, Brenda L., Hopkins, Sarah , Grasso, Eleonora A , McLendon, Loren A , Waldman, Amy Tara , Banwell, Brenda L

Mayo Clinic

Neurology | April 7, 2026 | Volume: 106 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000214926 | PMID 41945878 Get It

Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies
Sim, Austin J. , Hoppe, Bradford S. , Ballas, Leslie K, Milgrom, Sarah A. , Terezakis, Stephanie A, Ha, Chul S. , Figura, Nicholas , Parikh, Rahul R., Grecula, J.C., Flampouri, Stella , Kelsey, Christopher R, Parikh, Rahul R. , Parikh, Rahul R , Hoppe, Bradford S , Ballas, Leslie K. , Terezakis, Stephanie A , Plastaras, John Peter , Hodgson, David C. , Ryckman, Jeffrey M. , Pinnix, Chelsea C. , Kelsey, Chris R.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag112 | PMID 41965109 Get It

Abstract Modern radiation therapy (RT) technologies allow for improved sparing of normal tissues, decreasing the risk of both acute and long-term toxicities. Existing RT dose constraints for prospective trials within the National Clinical Trials Network (NCTN) were formulated in the context of solid malignancies. As patients with hematologic malignancies are often treated with lower RT doses and are usually younger with more favorable prognoses, customized dose constraints are needed. The NRG Oncology Hematologic Malignancies Working Group (NRG HEME) commissioned a review of existing organ-at-risk (OAR) constraints from published primary literature, the NRG Center for Innovation in Radiation Oncology (CIRO), and national guidelines. Customized constraints were developed by iterative review by NRG HEME. Final recommendations were approved by radiation oncology representatives from all the lymphoma NCTN groups (NRG Oncology, Children’s Oncology Group, Alliance, ECOG-ACRIN, SWOG, Canadian Cancer Trials Group). For 49 OARs, a strict recommended constraint was determined, of which 20 were not present in CIRO. Of the remaining 29 constraints, 20 were lower, 2 were the same, and 5 used different metrics; 2 were higher than at least 1 CIRO trial constraint. Acceptable variations were determined and unacceptable variations were added for select critical OARs for plan scoring. While doses to OARs without explicit unacceptable variations should not exceed acceptable variations, violations should not be considered for plan quality assessment on trials. This consensus list of standard OAR constraints should be incorporated for all future NCTN trials in hematologic malignancies. Strict dose constraints will minimize long-term toxicities in this patient population.
Antibiotic Prophylaxis in Dermatologic Surgery: Advisory Statement 2025 (APDSAS 2025)
Campbell, Elliott, Virk, Abinash, Lohman, Mary E. , Otley, Clark C. , Lessard, Sarah , Otley, Clark, Campbell, Elliott H. , Virk, Abinash

Mayo Clinic

Dermatologic Surgery | April 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005056 | PMID 41940644 Get It

BACKGROUND Guidelines and evidence related to antibiotic prophylaxis in dermatologic surgery have evolved since the authors' previously published advisory statement. OBJECTIVE To provide an updated advisory statement on antibiotic prophylaxis in dermatologic surgery as guided by updated recommendations from the American Heart Association and the American Dental Association with the American Academy of Orthopaedic Surgeons guidelines. METHODS A structured literature review was performed. A multidisciplinary team of specialists from dermatologic surgery, infectious diseases, and pharmacy were convened to review up-to-date data and develop updated comprehensive evidence-based recommendations. RESULTS Consistent with the previous advisory statement, prophylactic antibiotics are recommended for patients with high-risk cardiac or prosthetic joint conditions, when the dermatologic surgical site is infected or if the procedure breaches the mucosa. Significant changes were made for prophylaxis of surgical site infection. Updated recommendations were made regarding antibiotic selection in penicillin-allergic patients and intraoperative use of intraincisional clindamycin in the local anesthetic. LIMITATIONS Reviewed data are predominantly limited to retrospective data. CONCLUSION Recommendations regarding antibiotic prophylaxis around dermatologic surgery are evolving as new data and practices are introduced. The 2025 advisory statement provides the latest recommendations for appropriate use of antibiotic prophylaxis in dermatologic surgery.
The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome
Shemtov, Sarah J. , McGann, Eric, Carrillo, Lucy , Lee, Sangmin , Anson, Herbert, Chung, Claire S, Weinert, Jaye L., Anagnostou, Maria-Eleni, Lai, Guan-Ju, Verheijen, Bert M. , Wan, Junxiang , Vorobyova, Ivetta, Sanchez-Contreras, Monica, Conover, Cheryl A. , Thorwald, Max A. , Cohen, P., Kennedy, Scott R. , Goût, Jean-François , Haroon, Suraiya , Vermulst, Marc , Hwang, Eric , Chung, Claire S , Weinert, Jaye L , Lai, Guan-Ju D , Conover, Cheryl A , Thorwald, Max A , Cohen, Pinchas , Kennedy, Scott R , Gout, Jean-François , Vermulst, Marc , Anagnostou, Maria‐Eleni, Sánchez-Contreras, Mónica , Cohen, Pinchas

Mayo Clinic

Science Advances | April 3, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4279 | PMID 41931604 Get It

Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian life span and protects against a range of age-related diseases. Unexpectedly, we found that reduced IGF-1 signaling fails to extend the life span of mitochondrial mutator mice. Most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the prolongevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome, revealing an unexpected hierarchy in the pathways that control mammalian aging. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
Abstract 3156: Pharmacokinetics of a series of anticancer agents in immunodeficient female NOD scid gamma mice
Chama, Mohd Beshr, Koubek, Emily J. , Buhrow, Sarah A. , Schoon, Renee A., Reid, Joel M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3156-3156

10.1158/1538-7445.am2026-3156 Get It

Abstract Introduction: We aimed to characterize the preclinical pharmacokinetics (PK) of a series of 20 anticancer agents in highly immunodeficient female NOD scid gamma (NSG) mice to provide clearance and exposure data for agents under investigation by the NCI PDX Development and Trial Centers Research Network (PDXNet). Methods: The series of 20 anticancer agents (inhibitors of CDK4/6, PI3K-β/PI3K-δ, ATR, MEK1/2, PI3K, microtubule, EZH2, BCL-2, PARP, histone deacetylase, γ-secretase, FGFR, SHP2, and ERK1/2, as well as a SMAC mimetic) were administered to female NSG mice via IV, PO, or IP routes to characterize plasma exposures under conditions used for PDX efficacy testing. Serial plasma samples were collected 15, 30, 60, 120, 240, 360, 480, and 1440 minutes after dosing. Drug concentrations were quantified using validated LC-MS/MS assays. PK parameters were calculated using non-compartmental analysis. Results: The PK for each agent was determined, and the clearance and half-life values are listed in the table below. The PK metrics for Navitoclax could not be calculated. Due to higher metabolic rates, mice show faster PK processes. They generally had shorter half-lives and higher weight-normalized clearance than humans. Copanlisib, Navitoclax, and Trametinib were exceptions. Conclusion: These PK data are critical for understanding the antitumor activities of agents studied by the PDXNet and will aid investigators in developing new approach methodologies for preclinical safety studies in preparation for human clinical trials. Citation Format: Mohd Beshr Chama, Emily J. Koubek, Sarah A. Buhrow, Renee A. Schoon, Joel M. Reid. Pharmacokinetics of a series of anticancer agents in immunodeficient female NOD scid gamma mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3156.
Abstract 5051: A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history
Lan, Qing, Chan, John K., Lam, Tai Hing , Chen, Kexin, Kwong, Yok Lam, Xu, Caigang , Chiu, Brian CH, Liang, Raymond , Dennis, Ip, Hu, Wei, Bassig, Bryan A. , Purdue, Mark, Xu, Jun, Locke, Sarah J. , Wang, Sophia S., Berndt, Sonja, Hofmann, Jonathan N., Shi, Jianxin , Yu, Kai, Gadalla, Shahinaz, Jones, Rena, Dai, Hongji, Lyu, Zhangyan, Qiu, Lugui , Liu, Wei, zhang, huilai, Wang, Xianhuo, Chanock, Stephen, Linet, Martha, Vermeulen, Roel, Rothman, Nathaniel, Lan, Qing , Hurwitz, Lauren M. , Chan, John K.C., Chen, Kexin , Chiu, Brian C.‐H. , Cerhan, James R. , Hofmann, Jonathan N. , Gadalla, Shahinaz M. , McReynolds, Lisa J. , Jones, Rena R. , Qiu, Lugui , Liu, Wei , Zhang, Huilai , Wang, Xianhuo , Morton, Lindsay M. , Linet, Martha S. , Friesen, Melissa C. , Vermeulen, Roel , Rothman, Nathaniel

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5051-5051

10.1158/1538-7445.am2026-5051 Get It

Abstract Background: Epidemiologic and other studies have identified environmental, occupational, and genetic risk factors for lymphoid and myeloid malignancies, but most studies have been conducted in Western populations. Investigations in populations with differing exposure patterns, distributions of disease subtypes, and genetic architecture are needed to fully understand hematopoietic tumor etiology. Methods: We conducted a large, multicenter, hospital-based case-control study of lymphoid and myeloid neoplasms in East Asia (AsiaLymph), including 5,671 lymphoid cases, 1,879 myeloid cases, and 3,858 controls. Participants completed a computer-assisted personal interview and provided biospecimens. Cases underwent central pathology review and were coded into the WHO Classification. Herein, we describe the study methods in detail and report association results for education, body mass index, and family history. Results: Greater BMI at age 20 but not at age 40 was associated with odds of total lymphoid neoplasm (per 5 kg/m2 increase: OR [95% CI]: 1.18 [1.09-1.27]), total myeloid neoplasm (OR [95% CI]: 1.17 [1.05-1.29]), and several subtypes. Greater educational attainment was associated with increased odds of total lymphoid neoplasm (for college vs. less than primary education: OR [95% CI]: 1.41 [1.21-1.65]) but not myeloid neoplasm (OR [95% CI]: 1.17 [0.95-1.45]; p-heterogeneity=0.02). There were also positive associations between family history of hematologic cancer in first degree relatives and odds of lymphoid neoplasm (OR [95% CI]: 1.53 [1.15-2.03]) and myeloid neoplasm (OR [95% CI]: 1.65 [1.11-2.44]) and specific subtypes. None of the evaluated risk factors were associated with NK/T-cell lymphoma, which supports a distinct etiology for this subtype. Conclusion: The AsiaLymph Study is one of the largest molecular epidemiology studies of both lymphoid and myeloid neoplasms with standardized World Health Organization classification of histopathologic subtypes and will serve as a valuable resource for etiologic investigations into risk factors for these malignancies. Citation Format: Qing Lan, Lauren M. Hurwitz, John K. Chan, Tai Hing Lam, Kexin Chen, Yok Lam Kwong, Xu Caigang, Brian CH Chiu, Raymond Liang, Ip Dennis, Wei Hu, Bryan Bassig, Mark Purdue, Jun Xu, Sarah Locke, Sophia S. Wang, James R. Cerhan, Sonja Berndt, Jonathan N. Hofmann, Jianxin Shi, Kai Yu, Shahinaz Gadalla, Lisa J. McReynolds, Rena Jones, Hongji Dai, Zhangyan Lyu, Lugui Qiu, Wei Liu, Huilai Zhang, Xianhuo Wang, Lindsay M. Morton, Stephen Chanock, Martha Linet, Melissa C. Friesen, Roel Vermeulen, Nathaniel Rothman. A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5051.
Abstract 1067: Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance
Voorhees, Peter, Sookiasian, Danielle , Hess, Julian M. , DeMeo, M.K., Pounder, Vicki, Calkins, Sarah, Meyer, Reid G., Baughn, Linda B., Liacos, Christine-Ivy, Dimopoulos, Meletios-Athanasios, Papadimou, Alexandra , Konstantina, Taouxi, Kastritis, Efstathios, Auclair, Daniel, Nardi, Valentina , Mullen, Thomas D., Kumar, Shaji Kunnathu, Paiva, Bruno , Voorhees, Peter M. , Greipp, Patricia T. , Baughn, Linda B. , Liacos, Christine‐Ivy , Dimopoulos, Meletios Α. , Taouxi, Konstantina , Kastritis, Efstathios , Berdeja, Jesús G. , Auclair, Daniel , Mullen, Thomas, Aguet, François

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1067-1067

10.1158/1538-7445.am2026-1067 Get It

Abstract The detection of genetic abnormalities is required during diagnostic workup and for potential individualization of therapy selection in multiple myeloma (MM) and its precursor conditions. At present, this relies on invasive bone marrow (BM) biopsies, severely limiting early detection, frequent longitudinal monitoring, and the precise selection of therapy. The current standard for detecting genetic alterations in MM is fluorescence in situ hybridization (FISH), which cannot detect point mutations and other clinically relevant alterations. Consequently, the IMS-IMWG guidelines were recently updated to require next-generation sequencing for the classification of high-risk MM. To address these needs, we recently launched GenoPredicta, a CLIA-approved LDT that enables routine monitoring, informing diagnosis, and treatment selection by comprehensively characterizing MM genomes with whole genome sequencing (WGS) from as few as 50 circulating tumor cells (CTCs) isolated from peripheral blood (PB) or tumor cells from BM. Briefly, tumor cells are isolated from samples using fluorescence-activated cell sorting and subjected to WGS, from which copy number alterations, structural variants, and short variants (SNVs/indels) are identified using a fully automated pipeline generating physician-ready clinical reports from raw sequencing data in ∼6h. Analytical validation of GenoPredicta showed complete concordance with FISH results. Identifying alterations in therapeutic targets (e.g., BCMA, GPRC5D) for guiding MM immunotherapies is becoming increasingly important. Here, we describe GenoPredicta results from relapsed/refractory MM patients, highlighting resistance-conferring alterations that can only be detected by WGS, such as deletions in the kilo- to megabase scales that are observed in conjunction with SNVs and indels, leading to biallelic loss/inactivation of the gene, including at subclonal levels. In addition to biallelic loss of BCMA and GPRC5D in response to CAR T or T cell engager therapies, we observed similar resistance mechanisms for targets of immunomodulatory drugs, e.g., CRBN. The observation of these resistance mechanisms was consistent with patients’ clinical histories. In summary, we demonstrate that low input WGS-based characterization of MM from BM or CTCs is a viable replacement for FISH for clinical diagnosis and monitoring, with CTC-based measurements enabling comprehensive profiling of the MM genome. Crucially, this includes genetic alterations that confer resistance to therapy, allowing for both early detection of such alterations and more precise selection and guidance of therapy. The dramatically improved variant calling ability from WGS, especially in low-input CTC applications, extends to other malignancies and will gain wider adoption as sequencing costs continue to decrease. Citation Format: Bruno Paiva, Peter Voorhees, Patricia T. Greipp, Danielle Sookiasian, Julian Hess, Marisa DeMeo, Vicki Pounder, Sarah Calkins, Reid Meyer, Linda B. Baughn, Christine-Ivy Liacos, Meletios-Athanasios Dimopoulos, Alexandra Papadimou, Taouxi Konstantina, Efstathios Kastritis, Jesus Berdeja, Daniel Auclair, Valentina Nardi, Thomas Mullen, Francois Aguet, Shaji Kunnathu Kumar. Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1067.
Estimating Blood Volume Loss With Wireless, Wearable Ultrasound: A Pilot Investigation
Kenny, Jon‐Émile S. , Savery, Tracy, Lachner-Piza, Daniel, Eibl, Andrew M., Eibl, Joseph K. , Vungarala, Soumya , Dietz, Niki M., Kim, Chul-Ho, Johnson, Bruce D, Hebscher, Melissa , Atwi, Sarah , Piza, Daniel Lachner , Johnson, Bruce D.

Mayo Clinic

Military Medicine | April 2, 2026 | Volume: 191 | Issue: Supplement_1 | Pages: 386-392

10.1093/milmed/usag109 | PMID 42560273 Get It

Abstract Introduction Detecting and estimating blood volume loss are important for the diagnosis and management of life-threatening hemorrhage. There is a direct relationship between percent blood volume loss (BVL%) and falling in stroke volume (SV); furthermore, there is a direct relationship between diminishing SV and the corrected flow time of the carotid artery (ccFT). Therefore, we hypothesized that change in ccFT (ccFTΔ) would directly relate with BVL% in a phlebotomy paradigm. Materials and Methods A prospective, convenience sample of healthy volunteers was studied. Volunteers underwent blood donation protocol in a physiology lab. A wireless, wearable Doppler ultrasound system monitored ccFT during blood donation. Traditional vital signs were also measured throughout. The relationship between traditional vital signs as well as ccFTΔ were compared to BVL% using 2 mixed linear regression models. Results Data from 20 subjects and blood donations comprising 46,123 cardiac cycles are included. On average 413.5 ± 39 mL of blood were drawn representing 8.6 ± 1.6% BVL%. There was a significant and strong linear relationship between BVL% and ccFTΔ during blood draw with the regression slope demonstrating that for every 1 ms reduction in ccFT there was a 0.4% reduction in blood volume. Conclusions In healthy subjects and when blood loss is the sole mechanism for falling SV, we estimate that for every 1 ms reduction in ccFT, there is an approximate 0.4 BVL%. Validation of these results in patients with traumatic hemorrhage is underway.